Multiple studies highlighted new imaging-based approaches to identify patients at risk earlier or more precisely across oncology. One analysis in the EQUIP study reported that a next-generation 128 cm long-axial PET/CT scanner produced diagnostic-quality images in one minute, improving feasibility for faster workflows. Separately, a prospective study tied ultrafast dynamic contrast-enhanced MRI kinetic parameters—particularly maximum slope and time-to-enhancement—to axillary lymph node metastasis prediction in invasive breast cancer. In lung cancer, another prospective report described an MRI technique using amide proton transfer-weighted sequences that distinguished lung adenocarcinoma from squamous cell carcinoma in patients with spinal metastases without biopsy. Together, the findings emphasize a trend toward faster acquisition and more discriminative imaging biomarkers that could tighten patient selection for therapy—though broader external validation and prospective clinical impact still require confirmation.